1,700
Views
2
CrossRef citations to date
0
Altmetric
Clinical Research

Fomepizole dosing during continuous renal replacement therapy – an observational study

ORCID Icon, , , , , , , , , & show all
Pages 451-457 | Received 12 Aug 2021, Accepted 09 Sep 2021, Published online: 29 Sep 2021

References

  • Rostrup M, Edwards JK, Abukalish M, et al. The methanol poisoning outbreaks in Libya 2013 and Kenya 2014. PLoS One. 2016;11(3):e0152676.
  • Hassanian-Moghaddam H, Zamani N, Kolahi AA, et al. Double trouble: methanol outbreak in the wake of the COVID-19 pandemic in Iran-a cross-sectional assessment. Crit Care. 2020;24(1):402.
  • Karlson-Stiber C, Persson H. Ethylene glycol poisoning: experiences from an epidemic in Sweden. J Toxicol Clin Toxicol. 1992;30(4):565–574.
  • Hovda KE, Julsrud J, Øvreb ØS, et al. Studies on ethylene glycol poisoning: one patient – 154 admissions. Clin Toxicol. 2011;49(6):478–484.
  • McMartin K, Jacobsen D, Hovda KE. Antidotes for poisoning by alcohols that form toxic metabolites. Br J Clin Pharmacol. 2016;81(3):505–515.
  • McMartin KE, Hedstrom KG, Tolf BR, et al. Studies on the metabolic interactions between 4-methylpyrazole and methanol using the monkey as an animal model. Arch Biochem Biophys. 1980;199(2):606–614.
  • McMartin KE, Makar AB, Martin G, et al. Methanol poisoning. I. The role of formic acid in the development of metabolic acidosis in the monkey and the reversal by 4-methylpyrazole. Biochem Med. 1975;13(4):319–333.
  • Kraut JA, Mullins ME. Toxic alcohols. N Engl J Med. 2018;378(3):270–280.
  • Zakharov S, Pelclova D, Navratil T, et al. Intermittent hemodialysis is superior to continuous veno-venous hemodialysis/hemodiafiltration to eliminate methanol and formate during treatment for methanol poisoning. Kidney Int. 2014;86(1):199–207.
  • Zakharov S, Pelclova D, Navratil T, et al. Efficiency of acidemia correction on intermittent versus continuous hemodialysis in acute methanol poisoning. Clin Toxicol. 2017;55(2):123–132.
  • Zakharov S, Rulisek J, Nurieva O, et al. Intermittent versus continuous renal replacement therapy in acute methanol poisoning: comparison of clinical effectiveness in mass poisoning outbreaks. Ann Intensive Care. 2017;7(1):1–11.
  • Jobard E, Harry P, Turcant A, et al. 4-Methylpyrazole and hemodialysis in ethylene glycol poisoning. J Toxicol Clin Toxicol. 1996;34(4):373–377.
  • Faessel H, Houze P, Baud FJ, et al. 4-Methylpyrazole monitoring during haemodialysis of ethylene glycol intoxicated patients. Eur J Clin Pharmacol. 1995;49(3):211–213.
  • Brent J. Fomepizole for ethylene glycol and methanol poisoning. N Engl J Med. 2009;360(21):2216–2223.
  • McMartin KE, Sebastian CS, Dies D, et al. Kinetics and metabolism of fomepizole in healthy humans. Clin Toxicol. 2012;50(5):375–383.
  • Mueller BA, Golper TA. Drug removal in continuous renal replacement therapy. UpToDate [Internet]. [cited 2020 Apr 29]. Available from: https://www.uptodate.com/contents/drug-removal-in-continuous-renal-replacement-therapy?csi=d48f8ef3-4790-4017-9dd5-e3879a637157&source=contentShare.
  • Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand. 2001;45(8):929–934.
  • Wu D, Cederbaum AI. Induction of liver cytochrome P4502E1 by pyrazole and 4-methylpyrazole in neonatal rats. J Pharmacol Exp Ther. 1993;264(3):1468–1473.
  • Feierman DE, Cederbaum AI. Oxidation of the alcohol dehydrogenase inhibitor pyrazole to 4-hydroxypyrazole by microsomes. Effect of cytochrome P-450 inducing agents. Drug Metab Dispos. 1987;15(5):634–639.
  • Jacobsen D, Sebastian CS, Barron SK, et al. Effects of 4-methylpyrazole, methanol/ethylene glycol antidote, in healthy humans. J Emerg Med. 1990;8(4):455–461.
  • Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for toxic alcohols study group. N Engl J Med. 1999;340(11):832–838.
  • Rasamison R, Besson H, Berleur M-P, et al. Analysis of fomepizole safety based on a 16-year post-marketing experience in France. Clin Toxicol. 2020;58(7):742–747.
  • Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Workgroup. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(2):1–138.
  • Schetz M, Ferdinande P, Van Den Berghe G, et al. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med. 1995;21(7):612–620.
  • Mayersohn M, Owens SM, Anaya AL, et al. 4-Methylpyrazole disposition in the dog: evidence for saturable elimination. J Pharm Sci. 1985;74(8):895–896.
  • McMartin KE, Collins TD. Distribution of oral 4-methylpyrazole in the rat: inhibition of elimination by ethanol. J Toxicol Clin Toxicol. 1988;26(7):451–466.
  • Wallemacq PE, Vanbinst R, Haufroid V, et al. Plasma and tissue determination of 4-methylpyrazole for pharmacokinetic analysis in acute adult and pediatric methanol/ethylene glycol poisoning. Ther Drug Monit. 2004;26(3):258–262.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.